Robert Edward Fuller

Array ( [id] => 16437079 [patent_doc_number] => 20200354405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => METHOD FOR ACTIVATING HELPER T CELL [patent_app_type] => utility [patent_app_number] => 16/835761 [patent_app_country] => US [patent_app_date] => 2020-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12747 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16835761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16437079 [patent_doc_number] => 20200354405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => METHOD FOR ACTIVATING HELPER T CELL [patent_app_type] => utility [patent_app_number] => 16/835761 [patent_app_country] => US [patent_app_date] => 2020-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12747 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16835761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283972 [patent_doc_number] => 20200277574 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => METHOD FOR MASS PRODUCING NATURAL KILLER CELL AND USE OF NATURAL KILLER CELL OBTAINED BY THE METHOD AS ANTI-CANCER AGENT [patent_app_type] => utility [patent_app_number] => 16/811063 [patent_app_country] => US [patent_app_date] => 2020-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16871 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16811063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16541003 [patent_doc_number] => 20200407416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof [patent_app_type] => utility [patent_app_number] => 16/812166 [patent_app_country] => US [patent_app_date] => 2020-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 76540 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16812166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16328414 [patent_doc_number] => 20200299380 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => MICA BINDING AGENTS [patent_app_type] => utility [patent_app_number] => 16/804705 [patent_app_country] => US [patent_app_date] => 2020-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55124 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16804705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19738530 [patent_doc_number] => 12215350 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-04 [patent_title] => Mononuclear cell derived NK cells [patent_app_type] => utility [patent_app_number] => 16/796226 [patent_app_country] => US [patent_app_date] => 2020-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 5344 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16796226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16421905 [patent_doc_number] => 20200347103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS [patent_app_type] => utility [patent_app_number] => 16/790370 [patent_app_country] => US [patent_app_date] => 2020-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 93480 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16790370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17505218 [patent_doc_number] => 20220098320 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => SENOLYTIC CAR-T CELLS TARGETING UPAR, A CELL SURFACE AND SECRETED SENESCENCE BIOMARKER [patent_app_type] => utility [patent_app_number] => 17/426728 [patent_app_country] => US [patent_app_date] => 2020-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43584 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17426728 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16189315 [patent_doc_number] => 20200230164 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => ACTIVATION OF iNKT CELLS [patent_app_type] => utility [patent_app_number] => 16/751638 [patent_app_country] => US [patent_app_date] => 2020-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12014 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16751638 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16328385 [patent_doc_number] => 20200299351 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => Antigen-Presenting Synthetic Surfaces, Covalently Functionalized Surfaces, Activated T Cells, and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/743849 [patent_app_country] => US [patent_app_date] => 2020-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 75971 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16743849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16108611 [patent_doc_number] => 20200206328 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => COMPOSITIONS, METHODS AND USES OF ALPHA 1-ANTITRYPSIN FOR EARLY INTERVENTION IN BONE MARROW TRANSPLANTATION AND TREATMENT OF GRAFT VERSUS HOST DISEASE [patent_app_type] => utility [patent_app_number] => 16/743940 [patent_app_country] => US [patent_app_date] => 2020-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24543 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16743940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16483968 [patent_doc_number] => 20200377569 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => SYNTAC POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/740752 [patent_app_country] => US [patent_app_date] => 2020-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47275 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16740752 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17443755 [patent_doc_number] => 20220064260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => ISOLATED MHC-DERIVED HUMAN PEPTIDES AND USES THEREOF FOR STIMULATING AND ACTIVATING THE SUPPRESSIVE FUNCTION OF CD8+CD45RCLOW TREGS [patent_app_type] => utility [patent_app_number] => 17/312161 [patent_app_country] => US [patent_app_date] => 2019-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19606 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17312161 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15993453 [patent_doc_number] => 20200172597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => ARTIFICIAL ANTIGEN PRESENTING CELLS INCLUDING HLA-E AND HLA-G MOLECULES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/702249 [patent_app_country] => US [patent_app_date] => 2019-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62080 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16702249 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17228890 [patent_doc_number] => 20210355446 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => ARTIFICIAL HLA-POSITIVE FEEDER CELL LINES FOR NK CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/293895 [patent_app_country] => US [patent_app_date] => 2019-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24695 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17293895 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15713285 [patent_doc_number] => 20200103408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => METHOD FOR THE ABSOLUTE QUANTIFICATION OF NATURALLY PROCESSED HLA-RESTRICTED CANCER PEPTIDES [patent_app_type] => utility [patent_app_number] => 16/685765 [patent_app_country] => US [patent_app_date] => 2019-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11204 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16685765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15646795 [patent_doc_number] => 20200085927 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => COMPOUND COMPRISING AN AUTOANTIGENIC PEPTIDE AND A CARRIER WITH A MHC BINDING MOTIF [patent_app_type] => utility [patent_app_number] => 16/685424 [patent_app_country] => US [patent_app_date] => 2019-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6444 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16685424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15828547 [patent_doc_number] => 20200129555 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => HLA-A3-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS [patent_app_type] => utility [patent_app_number] => 16/662808 [patent_app_country] => US [patent_app_date] => 2019-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16401 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16662808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16175583 [patent_doc_number] => 20200222551 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => COMPOSITIONS, METHODS AND USES FOR ALPHA-1 ANTITRYPSIN FUSION MOLECULES [patent_app_type] => utility [patent_app_number] => 16/598194 [patent_app_country] => US [patent_app_date] => 2019-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23137 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16598194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17256840 [patent_doc_number] => 20210369825 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => CD40 AND CD40L COMBO IN AN ADV VACCINE VEHICLE [patent_app_type] => utility [patent_app_number] => 17/277997 [patent_app_country] => US [patent_app_date] => 2019-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17770 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17277997 [rel_patent_id] =>[rel_patent_doc_number] =>)